Overview of a Scale-Up of a Cell-Based Influenza Virus Production Process

BPI Contributor

June 1, 2013

1 Min Read
Overview of a Scale-Up of a Cell-Based Influenza Virus Production Process


The aim of this white paper is to demonstrate how GE Healthcare Life Sciences single-use products can be applied in the field of vaccine manufacturing. A brief discussion around modern vaccine processes is followed by a case study showing the scale-up of upstream and downstream processes for the production of a cell based live attenuated influenza virus using single-use ReadyToProcess technology. Single-use equipment enables quick changeover between products, minimizes risk for cross-contamination between batches, and reduces the need for cleaning and validation operations.

You May Also Like